Research on Alzheimer’s disease (AD) indicates that oligomers of amyloid β42 (Aβ42) contribute to neuropathology. Park et al. designed a yeast-based high-throughput screen for compounds that inhibit aggregation of Aβ42 oligomers. Their pilot screen of 12,800 compounds identifies two molecules that are promising candidates for development into drugs appropriate for use in the CNS. These data put forward two new compounds worthy of testing in preclinical models of AD and establish a system to screen for new inhibitors of Aβ42 oligomerisation. Page 822
- Written by editorial staff. © 2011. Published by The Company of Biologists Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.